Black Diamond Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BDTX research report →
Range $8 – $20
Price Chart
About the company
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor.
- CEO
- Mark A. Velleca
- IPO
- 2020
- Employees
- 21
- HQ
- Cambridge, MA, US
Get TickerSpark's AI analysis on BDTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $103.72M
- P/E
- -2.47
- PEG
- 0.01
- P/S
- 0.00
- P/B
- 1.09
- EV/EBITDA
- -2.51
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -38.80%
- ROIC
- -45.91%
Latest fiscal year · YoY change
- Revenue
- $70.00M+0.0%
- Gross Profit
- $69.67M+0.0%
- Op Income
- $19.87M
- Net Income
- $22.37M+132.1%
- EPS
- $0.39+130.7%
- OCF Growth
- +147.5%
- FCF Growth
- +147.5%
- 52W High
- $4.94
- 52W Low
- $1.60
- 50D MA
- $1.99
- 200D MA
- $2.25
- Beta
- 3.33
- RSI (14)
- 41
- Avg Volume
- 624.32K
No earnings-call transcripts are available for BDTX yet.
- Free Float
- 80.3%
- Shares Outstanding
- 57.30M
- Float Shares
- 46.02M
of shares held by institutions
108 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Nea Management Company, LLC | 4.45M | 0 |
| T. Rowe Price Investment Management, Inc. | 4.03M | ▼ 6.53M |
| Blackrock, Inc. | 3.92M | ▲ 2.81M |
| Acadian Asset Management LLC | 2.35M | 0 |
| Vanguard Group Inc | 2.19M | 0 |
| Vanguard Capital Management LLC | 2.13M | ▲ 274.80K |
| Renaissance Technologies LLC | 1.96M | ▲ 318.65K |
| Defilade Capital Management, L.P. | 1.67M | ▲ 1.67M |
| Dimensional Fund Advisors LP | 1.37M | ▲ 63.72K |
| Geode Capital Management, LLC | 1.22M | ▲ 681.60K |
| Connor, Clark & Lunn Investment Management Ltd. | 1.09M | ▲ 34.49K |
| Awm Investment Company, Inc. | 1.00M | ▲ 475.00K |
Held by 110 ETFs
Biggest fund positions in BDTX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 18, 26 | Behbahani Ali | other | 7,707 |
| Sep 18, 26 | Raman Prakash | other | 6,801 |
| Jun 26, 26 | Behbahani Ali | other | 40,000 |
| Jun 26, 26 | Kulkarni Samarth | other | 40,000 |
| Jun 26, 26 | Menzel Garry E | other | 40,000 |
| Jun 26, 26 | Raman Prakash | other | 40,000 |
| Jun 26, 26 | Dhingra Kapil | other | 40,000 |
| Jun 26, 26 | Campbell Shannon | other | 40,000 |
| Jun 19, 26 | Behbahani Ali | other | 8,961 |
| Jun 19, 26 | Raman Prakash | other | 7,907 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BDTX coverage
Recent articles, reports, and earnings notes.
Want a deeper read on BDTX?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Critical Contrast: Absci (NASDAQ:ABSI) and Black Diamond Therapeutics (NASDAQ:BDTX)
defenseworld.net · Oct 8
Reviewing Pliant Therapeutics (NASDAQ:PLRX) & Black Diamond Therapeutics (NASDAQ:BDTX)
defenseworld.net · Sep 11
Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
globenewswire.com · Sep 2
Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com · Aug 5
Black Diamond Therapeutics: Positive Phase 2 Results Offer An Upside
seekingalpha.com · Jul 6
BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst
zacks.com · May 27
Black Diamond Stock Outlook After Q1 Beat and Cash Runway
zacks.com · May 27
BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know
zacks.com · May 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.